Podcast

Mapping Multiple Myeloma Advances in NYC

Author(s):

Onclive Team

In Partnership With:

We traveled to New York City, New York, for a State of the Science Summit™ on Multiple Myeloma, which featured insights from the faculty from the Mount Sinai Hospital.

We recently traveled to New York City, New York, for a State of the Science Summit™ on Multiple Myeloma. We met with experts from Mount Sinai Hospital to gather updates on emerging treatment strategies in multiple myeloma, including headway made with CAR T-cell therapies, the role of genomics, the shift toward personalized medicine, and progress made with maintenance therapies.

Related Videos
Douglas W. Sborov, MD, MS
Meletios (Thanos) Dimopoulos, MD, professor, therapeutics, Hematology Oncology, National and Kapodistrian University of Athens School of Medicine
Michel Delforge, MD, PhD
Ashraf Z. Badros, MBCHB, professor, medicine, Medical Oncology, Hematology Oncology, University of Maryland Medical System
Binod Dhakal, MD
Michel Delforge, MD, PhD, professor, Faculty of Medicine, Department of Hematology, director, member, Leuven Cancer Institute, member, Senior Academic Staff, Council of the Faculty of Medicine, Council of the Department of Oncology, University Hospital Leuven, University of Leuven
Ajay K. Nooka, MD, MPH, FACP
Meletios A. Dimopoulos, MD
Binod Dhakal, MD
In this final episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil, discuss plans for developing guidelines and policies to enhance management of bispecific T-cell engagers across various centers.
Related Content
David R. Oveisi, MD
November 20th 2024

Expanded Indications for CAR T-Cell Therapies Shepard in New Era of Myeloma Care

Susana M. Campos, MD, MPH
November 21st 2024

Trastuzumab Deruxtecan Advances HER2+ Gynecologic Cancer Care: With Susana M. Campos, MD, MPH

Multiple myeloma Image credit: LASZLO – stock.adobe.com
November 15th 2024

Isatuximab Plus VRd Earns CHMP Recommendation for Newly Diagnosed, Transplant-Ineligible Myeloma

Jaffer A. Ajani, MD, GI medical oncologist, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
November 14th 2024

FDA Approval Insights: Zolbetuximab for CLDN18.2+ HER2-Negative Gastric and GEJ Adenocarcinoma

FDA, EMA Receive Applications for Subcutaneous Daratumumab in High-Risk Smoldering Myeloma
November 8th 2024

FDA, EMA Receive Applications for Subcutaneous Daratumumab in High-Risk Smoldering Myeloma

FDA
November 6th 2024

FDA Grants Orphan Drug Designation to LBL-034 for Multiple Myeloma